Merck Ends Talks to Buy Cancer Biotech Revolution Medicines in $30B Deal
Merck has walked away from negotiations to acquire Revolution Medicines after failing to agree on price for the promising cancer drug developer valued around $30 billion.
/ 19 items
#MRK↓
Moderna Surges 69% in 2026 as Cancer Vaccine Shows Five-Year Melanoma Survival Benefits
Moderna stock jumped as five-year data from its personalized cancer vaccine trial with Merck showed a 49% reduction in melanoma recurrence risk, boosting hopes for mRNA's future in oncology.
Tempus AI Hits Major Milestone with $1.1 Billion in Contracts
Tempus AI achieves record $1.1 billion in total contract value, partners with 70+ pharmaceutical companies, and reports 31% revenue growth in 2025.
Merck Eyes $28-32 Billion Deal for Cancer Drugmaker Revolution Medicines
Merck negotiates potential acquisition of Revolution Medicines for up to $32B, seeking new cancer treatments as Keytruda patent expiration looms in 2028.
Trump Administration Secures Drug Price Cuts from Nine Major Pharmaceutical Companies
Nine pharmaceutical giants including Merck and GSK agree to slash U.S. drug prices to match other wealthy nations under new Trump administration deals, offering discounts up to 70%.
Adagene's Cancer Treatment Gets FDA Fast Track Status
Adagene receives FDA Fast Track designation for muzastotug, a novel cancer therapy targeting hard-to-treat colorectal cancer patients.